van Zuylen L - Search Results

1

Development of multidrug-resistance convertors: sense or nonsense?

van Zuylen L, Nooter K, Sparreboom A, Verweij J. van Zuylen L, et al. Invest New Drugs. 2000 Aug;18(3):205-20. doi: 10.1023/a:1006487003814. Invest New Drugs. 2000. PMID: 10958589 Review.

2

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. van Zuylen L, et al. Clin Cancer Res. 2000 Jul;6(7):2598-603. Clin Cancer Res. 2000. PMID: 10914699

3

Role of formulation vehicles in taxane pharmacology.

van Zuylen L, Verweij J, Sparreboom A. van Zuylen L, et al. Invest New Drugs. 2001 May;19(2):125-41. doi: 10.1023/a:1010618632738. Invest New Drugs. 2001. PMID: 11392447 Review.

4

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

Loos WJ, de Bruijn P, van Zuylen L, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: van zuylen l. J Chromatogr B Biomed Sci Appl. 1999 Dec 10;735(2):293-7. doi: 10.1016/s0378-4347(99)00414-4. J Chromatogr B Biomed Sci Appl. 1999. PMID: 10670744

5

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: van beurden v, van der gaast a, van der burg me. Clin Cancer Res. 2000 Apr;6(4):1365-71. Clin Cancer Res. 2000. PMID: 10778964 Clinical Trial.

6

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A. van Zuylen L, et al. Anticancer Drugs. 2000 Jun;11(5):331-7. doi: 10.1097/00001813-200006000-00003. Anticancer Drugs. 2000. PMID: 10912949 Clinical Trial.

7

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. van Zuylen L, et al. Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18. doi: 10.1007/s002800000215. Cancer Chemother Pharmacol. 2001. PMID: 11345647 Clinical Trial.

8

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: van der gaast a. Eur J Cancer. 2002 May;38(8):1090-9. doi: 10.1016/s0959-8049(02)00035-7. Eur J Cancer. 2002. PMID: 12008197

9

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Among authors: van zuylen l. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

10

Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

van Zuylen L, Schellens JH, Goey SH, Pronk LC, de Boer-Dennert MM, Loos WJ, Ma J, Stoter G, Verweij J. van Zuylen L, et al. Anticancer Drugs. 1999 Apr;10(4):361-8. doi: 10.1097/00001813-199904000-00003. Anticancer Drugs. 1999. PMID: 10378670 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters